# EMN02 (NCT01208766)

> Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: melphalan; VRD
- Indication: newly diagnosed multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01208766
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
- Conditions: Multiple Myeloma
- Interventions: Bortezomib, Melphalan, Prednisone (VMP); 1 or 2 cycle(s) HDM (High Dose Melphalan); 2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)
- Enrollment: 1503
- Primary outcome: For all registered patients: progression free survival (PFS) as defined by time from registration to progression or death from any cause (whichever occurs first).
- Primary outcome: For all patients included in R1; PFS as defined by time from randomization R1 to progression or death from any cause whichever comes first
- Primary outcome: For all patients included in R2; PFS as defined by time from randomization R2 to progression or death from any cause whichever comes first

## Indexed commentary on EMN02 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 22
- YouTube: 14

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=emn02-nct01208766

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01208766", "email": "<work email>"}; the inbox owner confirms by the emailed link.